Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received a consensus recommendation of “Buy” from the six research firms that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $18.60.

Several research firms have commented on LNTH. BidaskClub lowered shares of Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 17th. Zacks Investment Research upgraded shares of Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $18.00 price objective for the company in a research note on Thursday, August 3rd. Credit Suisse Group increased their price objective on shares of Lantheus Holdings from $14.00 to $19.00 and gave the company a “neutral” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $22.00 price objective (up previously from $18.00) on shares of Lantheus Holdings in a research note on Wednesday, August 2nd. Finally, Cantor Fitzgerald began coverage on shares of Lantheus Holdings in a research note on Monday, July 17th. They issued an “overweight” rating and a $22.00 price objective for the company.

Lantheus Holdings (NASDAQ LNTH) opened at 16.50 on Monday. The firm has a market cap of $616.28 million, a P/E ratio of 22.54 and a beta of 0.94. The firm’s 50-day moving average price is $17.42 and its 200-day moving average price is $15.26. Lantheus Holdings has a 12 month low of $7.18 and a 12 month high of $20.45.

Lantheus Holdings (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported $0.42 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.18. The firm had revenue of $88.83 million during the quarter, compared to analyst estimates of $80.56 million. Lantheus Holdings had a net margin of 8.44% and a negative return on equity of 37.47%. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter last year, the business posted $0.24 EPS. On average, equities research analysts expect that Lantheus Holdings will post $1.12 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/11/lantheus-holdings-inc-lnth-receives-consensus-recommendation-of-buy-from-analysts.html.

In other news, major shareholder Avista Capital Partners Gp, Ll sold 87,939 shares of the firm’s stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $17.40, for a total transaction of $1,530,138.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Cesare Orlandi sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $16.69, for a total transaction of $300,420.00. Following the sale, the insider now owns 87,078 shares of the company’s stock, valued at approximately $1,453,331.82. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,768,386 shares of company stock valued at $57,813,141. 2.30% of the stock is currently owned by company insiders.

Several hedge funds have recently modified their holdings of LNTH. Trexquant Investment LP purchased a new position in Lantheus Holdings in the 1st quarter valued at approximately $332,000. Systematic Financial Management LP purchased a new position in Lantheus Holdings in the 1st quarter valued at approximately $1,314,000. Nordea Investment Management AB grew its stake in Lantheus Holdings by 23.7% in the 1st quarter. Nordea Investment Management AB now owns 127,700 shares of the medical equipment provider’s stock valued at $1,596,000 after buying an additional 24,500 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Lantheus Holdings by 6.3% in the 1st quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock valued at $856,000 after buying an additional 4,084 shares in the last quarter. Finally, FNY Partners Fund LP purchased a new position in Lantheus Holdings in the 1st quarter valued at approximately $174,000. Institutional investors own 84.35% of the company’s stock.

About Lantheus Holdings

Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.

Receive News & Ratings for Lantheus Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.